Chemomab Therapeutics Ltd. Income (Loss) from Continuing Operations, Per Diluted Share
Chemomab Therapeutics Ltd. (CMMB) reported Income (Loss) from Continuing Operations, Per Diluted Share of $0.02 per share for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-03-23
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|
| 2025-12-31 | $0.02 20-F · filed 2026-03-23 | |
| 2025-06-30 | $0.01 6-K · filed 2025-08-14 | |
| 2024-12-31 | $0.04 20-F · filed 2026-03-23 | |
| 2024-06-30 | $0.03 6-K · filed 2025-08-14 | |
| 2023-12-31 | $0.10 20-F · filed 2026-03-23 | |
| 2022-12-31 | $0.12 20-F · filed 2025-04-04 | |
| 2021-12-31 | $0.06 20-F · filed 2024-03-28 |